Free Trial

NextCure (NXTC) 10K Form and Latest SEC Filings 2026

NextCure logo
$10.25 +0.45 (+4.59%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$10.24 -0.01 (-0.05%)
As of 05/14/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest NextCure SEC Filings & Recent Activity

NextCure (NASDAQ:NXTC) has submitted 235+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form SCHEDULE 13G/A submitted on May 13, 2026.

8-K
NextCure Files Current Report on May. 7, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
NextCure Files Annual Report on Mar. 5, 2026

The 10-K contains NextCure's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

NextCure SEC Filing History

Browse NextCure's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/13/2026 3:42 PM
NextCure (1661059) Subject
SILVERARC CAPITAL MANAGEMENT, LLC (1816307) Filed by
Form SCHEDULE 13G/A
05/07/2026 3:19 PM
NextCure (1661059) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2026 8:26 PM
NextCure (1661059) Subject
Simcere Zaiming, Inc. (2080252) Filed by
Form SCHEDULE 13G/A
04/24/2026 3:15 PM
NextCure (1661059) Filer
Form DEF 14A
04/24/2026 3:18 PM
NextCure (1661059) Filer
Form DEFA14A
03/05/2026 3:26 PM
NextCure (1661059) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/05/2026 3:15 PM
NextCure (1661059) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2026 5:06 AM
NextCure (1661059) Subject
Sofinnova Venture Partners IX, L.P. (1612133) Filed by
Form SCHEDULE 13D/A
02/17/2026 4:28 PM
Ikarian Capital, LLC (1778253) Filed by
NextCure (1661059) Subject
Form SCHEDULE 13G
02/17/2026 11:00 AM
NextCure (1661059) Subject
Squadron Capital Management LLC (2050709) Filed by
Form SCHEDULE 13G/A
02/12/2026 11:05 AM
NextCure (1661059) Subject
SILVERARC CAPITAL MANAGEMENT, LLC (1816307) Filed by
Form SCHEDULE 13G
01/29/2026 8:33 PM
Affinity Asset Advisors, LLC (1773195) Filed by
NextCure (1661059) Subject
Form SCHEDULE 13G/A
01/23/2026 6:20 AM
NextCure (1661059) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/19/2025 4:29 PM
NextCure (1661059) Filer
Form 424B5
12/19/2025 4:31 PM
NextCure (1661059) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/11/2025 11:15 PM
NextCure (1661059) Filer
Form EFFECT
12/11/2025 3:59 PM
NextCure (1661059) Filer
Form 424B1
12/09/2025 8:32 PM
NextCure (1661059) Filer
Form D
Notice of Exempt Offering of Securities 
11/17/2025 7:20 AM
NextCure (1661059) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/05/2025 3:25 PM
NextCure (1661059) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/05/2025 3:16 PM
NextCure (1661059) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2025 3:37 PM
NextCure (1661059) Subject
Squadron Capital Management LLC (2050709) Filed by
Form SCHEDULE 13G
09/29/2025 3:00 PM
Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (2088064) Reporting
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. (2082506) Reporting
NextCure (1661059) Issuer
Ren Jinsheng (1455397) Reporting
Simcere Pharmaceutical Group Ltd (2082516) Reporting
Simcere Zaiming, Inc. (2080252) Reporting
Tang Renhong (2088593) Reporting
Form 3/A
08/25/2025 3:11 PM
NextCure (1661059) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/19/2025 8:46 PM
NextCure (1661059) Subject
Simcere Zaiming, Inc. (2080252) Filed by
Form SCHEDULE 13G
08/19/2025 8:32 PM
NextCure (1661059) Issuer
Simcere Zaiming, Inc. (2080252) Reporting
Form 3
Initial statement of beneficial ownership of securities  
07/29/2025 11:15 PM
NextCure (1661059) Filer
Form EFFECT
07/14/2025 6:15 AM
NextCure (1661059) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/10/2025 8:00 AM
NextCure (1661059) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/24/2025 3:30 PM
Feigal Ellen (1758108) Reporting
NextCure (1661059) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 3:30 PM
NextCure (1661059) Issuer
Webster Stephen W (1438421) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 3:30 PM
Borgman Anne Elizabeth (1886388) Reporting
NextCure (1661059) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 3:31 PM
KABAKOFF DAVID S (1024008) Reporting
NextCure (1661059) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 3:31 PM
Jones Elaine V (1296907) Reporting
NextCure (1661059) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 3:31 PM
Houston John G (1753537) Reporting
NextCure (1661059) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025 8:15 AM
NextCure (1661059) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/16/2025 6:15 AM
NextCure (1661059) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/19/2025 3:20 PM
NextCure (1661059) Filer
Form DEFA14A
05/19/2025 3:22 PM
NextCure (1661059) Filer
Form DEFA14A
(Data available from 1/1/2016 forward)

NextCure SEC Filings - Frequently Asked Questions

NextCure (NXTC) has submitted 235+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

NextCure's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form SCHEDULE 13G/A submitted on May 13, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:NXTC) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners